Navigation Links
Shire to Enter European ADHD Market With the Acquisition of EQUASYM(R) IR and XL
Date:2/20/2009

PHILADELPHIA and DUBLIN, February 20 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that it has signed an agreement with UCB to acquire the worldwide rights to EQUASYM(R) IR and XL (methylphenidate hydrochloride) (excluding the USA, Canada and Barbados) used for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).

EQUASYM XL is approved and marketed in 10 countries (outside the USA, Canada, and Barbados), and EQUASYM IR is currently approved and marketed in four countries. In 2008 the products generated aggregate net sales of EUR16.9 million in these territories.

This acquisition will broaden the scope of Shire's ADHD portfolio and will facilitate immediate access to the European ADHD market as well as provide Shire the opportunity to enter additional world markets. EQUASYM will allow Shire to build on its status as the leader in the United States ADHD market with patients and customers in Europe and establishes a solid bridge for Shire's other ADHD treatments in territories outside of the United States. VYVANSE(R) (lisdexamfetamine dimesylate), used for the treatment of ADHD in pediatric and adult patients, was launched by Shire in the United States in July 2007 and is in Phase 3 trials in Europe.

As part of this transaction, approximately 20 sales and sales management personnel will transfer to Shire, providing an established sales force for EQUASYM and other potential ADHD products.

Michael Cola, President of Shire's Specialty Pharmaceuticals business, commented:

"The acquisition of the EQUASYM franchise accelerates the establishment of Shire's ADHD presence in markets outside of North America. Our expertise and portfolio of ADHD products will provide a strong foundation from which
'/>"/>

SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion
2. Shire Receives FOSRENOL Paragraph IV Notice Letters from Barr Laboratories and Mylan
3. Shire plc: Change to Directors Details
4. Shire Successfully Settles Former TKT Shareholder Appraisal Rights Litigation
5. Shires New Product Portfolio Delivers Strong Quarterly Performance
6. Change of Name to Shire plc
7. Shire Announces Holding of 81% in Jerini AG and Publication of Offer Document
8. Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade.
9. Shire Re-Launches ADHDSupport.com, a Virtual Road Map Providing Information, Tools and Practical Tips About Attention Deficit Hyperactivity Disorder (ADHD)
10. Shire Ltd.: Robin Buchanan to Step Down as Non-Executive Director on Completion of Term of Office
11. Shire Ltd - Second Quarter 2008 Results Date Notification - 31 July 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 /CNW/ - Sunovion Pharmaceuticals ... APTIOM TM (eslicarbazepine acetate) for use as a ... in patients with epilepsy who are not satisfactorily controlled ... for use in patients under 18 years of age. ... common neurological disorders and according to Epilepsy Canada, it ...
(Date:7/10/2014)... July 10, 2014 Deep Knowledge ... Medicine Forum on ‘Commercialising Longevity Research’ and welcomed ... to the London Bioscience Innovation Center for the ... and Aging Analytics Ltd. The meeting highlighted the ... translational research for age-related disease, as well as ...
(Date:7/10/2014)... 2014 OMICS Group’s 5th International conference ... August, 2014 at Double Tree by Hilton Beijing, China ... in Analytical & Bioanalytical research methods only to facilitate ... this occasion, Dr. Srinubabu Gedela, MD of OMICS Group ... a remarkable one in bringing a unique and international ...
(Date:7/10/2014)... , July 10, 2014  Kainos Capital, a firm ... today announced that it has acquired the Slim-Fast brand ... the business. Terms of the transaction were not disclosed. ... meal replacement business that markets ready-to-drink shakes, powders, bars ... America and in the United ...
Breaking Biology Technology:Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Kainos Capital Acquires Slim-Fast From Unilever 2
... 2011 Dyadic International, Inc. ("Dyadic") (OTC Pink: ... discovery, development, manufacture and sale of enzyme and ... biopharmaceutical industries, today announced financial results for the ... contained in this press release should be read ...
... 2011 SynCo Bio Partners B.V., one of ... its aseptic filling facility is again fully operational and SynCo ... its clients after the expansion of its Class A zone. ... is an important milestone in SynCo,s strategy in supporting its ...
... Gram for gram, novel carbon nanofiber-filled coatings devised by ... (NIST) and Texas A&M University outperformed conventional flame retardants ... mattresses by at least 160 percent and perhaps by ... results, reported in the journal Polymer ,* suggest ...
Cached Biology Technology:Dyadic International Reports 2011 Second Quarter Financial Results 2Dyadic International Reports 2011 Second Quarter Financial Results 3Dyadic International Reports 2011 Second Quarter Financial Results 4Dyadic International Reports 2011 Second Quarter Financial Results 5Dyadic International Reports 2011 Second Quarter Financial Results 6Dyadic International Reports 2011 Second Quarter Financial Results 7SynCo Bio Partners Expands the Class A Zone in its Aseptic Filling Facility 2Novel coatings show great promise as flame retardants in polyurethane foam 2
(Date:7/11/2014)... Bone and Mineral Research awarded Michael F. Holick, PhD, ... the 2014 Louis V. Avioli Award. Holick, a professor ... known for revolutionizing the understanding of vitamin D and ... honors a member of the American Society for Bone ... and mineral basic research. It is named for ASBMR,s ...
(Date:7/11/2014)... German . ... refraction of X-rays through a specimen instead of attenuation ... are often of much higher quality than those based ... Franz Pfeiffer are particularly interested in developing new approaches ... phase-contrast imaging. One main goal is to make this ...
(Date:7/11/2014)... of Standards and Technology (NIST) need a special ... often prove that necessity is truly the mother ... M. Lorna De Leoz and Stephen Stein, NIST ... Glycomics is the study of the abundant, often-branched ... proteins and lipids and influence cellular processes, including ...
Breaking Biology News(10 mins):BUSM's Michael F. Holick receives American Society for Bone and Mineral Research award 2New simple setup for X-ray phase contrast 2
... Rockies are stifling the mating choices of butterflies in ... and less abundant alpine meadows--largely the result of human ... pattern that could lead to the butterflies being less ... scientist at the University of Alberta and an author ...
... immediate wake of Hurricane Katrina, scientists and research centers ... on the contaminated floodwaters and offer it to hazardous ... matter of hours, the University of North Carolina at ... (RENCI), together with the National Center for Supercomputing Applications ...
... the University of Chicago has developed a non-invasive laboratory technique ... off and on in a living bacterium as it becomes ... The technique, which is announced in the Monday, June 13 ... could help scientists discover new drugs and learn to what ...
Cached Biology News:Expanding forests darken the outlook for butterflies, study shows 2UNC computer, marine scientists collaborate to predict flow of toxic waters from Katrina 2UNC computer, marine scientists collaborate to predict flow of toxic waters from Katrina 3Scientists devise way to measure RNA synthesis on the fly in a live cell 2
Human Norrin Biotinylated Affinity Purified PAb Protein Family: Other Growth Factors, Other Wnt-related Molecules...
...
Recombinant Mouse Matrilin-4, CF Protein Family: Extracellular Matrix Molecules, Chondrogenesis Markers...
Request Info...
Biology Products: